Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

April 2021

Multiple authors, the SEQC2 Oncopanel Sequencing Working Group

A multi-site and cross-platform evaluation of circulating tumor DNA (ctDNA) NGS assays was conducted by the SEQC2 Oncopanel Sequencing Working Group and reported on in this comprehensive study. Five assays were tested for accuracy, sensitivity and reproducibility including simulations with spike-in DNA. This study is intended to report the state-of-the-art of these assays and inform best practices.

Pippin Prep was used to size select the ctDNA reference samples using 110 bp start and 190 bp end settings for an average fragment length of ~150 bp.

Nature Biotechnology
DOI: 10.1038/s41587-021-00857-z

This entry was posted in Citation and tagged , , , . Bookmark the permalink.

Comments are closed.